Hrain Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2015-07-20
- Employees
- 101
- Market Cap
- -
- Website
- http://www.dashengbio.com
Clinical Trials
13
Active:1
Completed:0
Trial Phases
3 Phases
Early Phase 1:6
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Early Phase 1
6 (46.2%)Phase 1
5 (38.5%)Phase 2
2 (15.4%)Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Early Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06760260
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Early Phase 1
Recruiting
- Conditions
- Multiple MyelomaPlasma Cell Leukemia
- Interventions
- Drug: Human BCMA targeted CAR-NK cells injection
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06045091
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Early Phase 1
Recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT05651191
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Early Phase 1
Recruiting
- Conditions
- Central Nervous System Lymphoma
- Interventions
- Drug: Human CD19-CD22 Targeted T Cells Injection
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05651178
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Human BCMA Targeted T Cells Injection
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05594797
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
- Prev
- 1
- 2
- 3
- Next
News
No news found